D3 Partial Agonists for CNS Therapy With Fewer Dopamine Side Effects

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for central nervous system disorders such as Restless Leg Syndrome (RLS), Parkinson's disease, Alzheimer's disease, and Huntington's disease, using full dopamine D2/D3 agonists, face issues like side effects (nausea, vomiting, behavioral disorders, and long-term efficacy loss) due to receptor over-stimulation.

Innovation Solution

A compound, BP1.4979, with partial D3 agonist and D2 antagonist activity, is developed to treat these disorders, offering reduced side effects and sustained efficacy.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If full dopamine D2/D3 agonists are used to treat CNS disorders, then therapeutic efficacy is improved, but side effects (nausea, vomiting, behavioral disorders) increase due to receptor over-stimulation

Engineering Contradiction:

Improvetherapeutic efficacyVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial action by using a partial D3 agonist (BP1.4979) that activates the D3 receptor to a limited extent rather than full activation. This partial agonism provides sufficient therapeutic effect for RLS and neurodegenerative diseases while avoiding the excessive stimulation that causes nausea, vomiting, and behavioral disorders. The compound achieves this by having lower intrinsic activity compared to full agonists like pramipexole or rotigotine.

Inventive Principle:

Principle #16Partial or excessive action

Solution Approach 2:

The patent changes the pharmacological parameter of receptor activation from full agonism to partial agonism. By modifying the compound's affinity and intrinsic activity at the D3 receptor, BP1.4979 provides a new activation level that balances therapeutic efficacy with reduced side effects. This parameter change allows the system to achieve therapeutic goals without the harmful over-stimulation of conventional full agonists.

Inventive Principle:

Principle #35Parameter changes

2Duration of action of stationary object

If full dopamine D2/D3 agonists are used for long-term treatment, then disease management is achieved, but loss of efficacy and augmentation of symptoms occur

Engineering Contradiction:

Improvelong-term treatment durationVSAvoidefficacy stability

Core Design Contradiction:

Duration of action of stationary objectVSReliability

Solution Approach 1:

The patent uses partial agonism to avoid the tolerance development and augmentation phenomena associated with long-term full agonist use. By providing sub-maximal stimulation, the partial agonist BP1.4979 maintains stable efficacy over time without causing receptor desensitization or symptom augmentation, thereby improving long-term treatment reliability.

Inventive Principle:

Principle #16Partial or excessive action

3Reliability

If full D2/D3 agonists are used to stimulate autophagy in neurodegenerative diseases, then neuronal degeneration is prevented, but harmful side effects are produced

Engineering Contradiction:

ImproveneuroprotectionVSAvoidside effects

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies partial agonism at the D3 receptor to achieve sufficient autophagy stimulation for neuroprotection without the harmful side effects of full agonists. BP1.4979 provides the necessary dopaminergic signaling to activate autophagy and clear toxic proteins while maintaining a lower activation level that avoids gastrointestinal and behavioral adverse effects.

Inventive Principle:

Principle #16Partial or excessive action

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

BP1.4979 demonstrates equivalent therapeutic effects to full dopamine agonists in RLS and neurodegenerative diseases, without common side effects, and shows potential in treating binge eating disorder.

Implementation Method 1

BP1.4979 is a D3 partial agonist and a D2 antagonist. The structure and process of preparation of BP1.4979 are disclosed in WO 2007/148208.

Methodology Applied

Scientific EffectDopamine D3 receptor activation:

Implementation Method 2

BP1.4979 is a D3 partial agonist and a D2 antagonist.

Methodology Applied

Scientific EffectDopamine D2 receptor antagonism:

Implementation Method 3

Wang et al. Autophagy, 2015, 11, 2057-2073. It was shown in particular that autophagy could be enhanced by pramipexole, a full D3/D2 agonist and its effect was blocked by a pure D3-receptor antagonist.

Methodology Applied

Scientific EffectAutophagy activation:

Data Source

PatentUS12582648B2Method for treating central nervous system disorders using dopamine D3 partial agonists

Publication Date: 2026.03.24 BIOPROJET PHARMA

AI summary

Disclosed is a method of using D3 partial agonists for treating or inhibiting the restless leg syndrome, binge eating, essential tremor and neurodegenerative diseases, in particular D3 partial agonists/D2 antagonists.